Bibliothek

X
feed icon rss

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
Filter
  • Behavioral therapy  (1)
  • Vomiting  (1)
  • cis-platinum  (1)
  • 1
    Digitale Medien
    Digitale Medien
    Progress in reducing anticipatory nausea and vomiting: a study of community practice (1997)
    Springer
    Supportive care in cancer 6 (1997), S. 46-50 
    Details
    ISSN: 1433-7339
    Schlagwort(e): Key words Nausea ; Vomiting ; Chemotherapy ; Anticipatory ; Antiemetic
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract  Chemotherapy-related nausea and vomiting (NV) in 300 consecutive patients treated in community practices prior to the availability of 5-HT3 antiemetics (9/87 to 1/91) were compared with NV in a second sample of 300 patients treated after their commercial introduction (9/93 to 2/95). Eighty-six percent of the later patients received 5-HT3 antiemetics, and significantly fewer (43.3%) reported one or more episodes of posttreatment vomiting during their first four cycles of chemotherapy compared with those in the previous sample (55.0%: P 〈 .01). Identical numbers of both groups (79.3%) reported at least one episode of posttreatment nausea. A significant increase in the average duration of both posttreatment nausea (from 28.1 h to 37.2 h;P = 0.001) and posttreatment vomiting (from 10.9 h–16.5 h, P = .02) was found; no significant differences were seen in the reported severity of either symptom. The proportion of patients experiencing at least one episode of anticipatory nausea (31.0% vs 32.0%) or anticipatory vomiting (7.7% vs 6.3%) did not differ significantly (P 〉 0.5) between groups, nor were there significant differences in the duration or severity of anticipatory symptoms (P 〉 0.4 for all comparisons). The reduction in the frequency of posttreatment vomiting supports research findings of efficacy. Findings of an increase in duration of posttreatment nausea and emesis and no change in the frequency of posttreatment nausea or in anticipatory symptoms show a continuing need for progress in control of posttreatment emesis and emphasize the need for further research on the control of chemotherapy-induced nausea.
    Materialart: Digitale Medien
    URL: http://dx.doi.org/10.1007/s005200050131
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Artikel (Nationallizenzen)
    Volltext
  • 2
    Digitale Medien
    Digitale Medien
    Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics (1998)
    Springer
    Supportive care in cancer 6 (1998), S. 244-247 
    Details
    ISSN: 1433-7339
    Schlagwort(e): Key words Cancer ; Chemotherapy ; Antiemetics ; Anticipatory nausea and vomiting ; Behavioral therapy ; Anxiety
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract Cancer chemotherapy is known to lead to nausea and vomiting in a large proportion of cases. If emesis is severe it can lead in its turn to anticipatory nausea and vomiting (ANV), which cannot be controlled by antiemetic medication. The etiology of ANV and various methods that have been used to counteract the condition are discussed.
    Materialart: Digitale Medien
    URL: http://dx.doi.org/10.1007/s005200050161
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Artikel (Nationallizenzen)
    Volltext
  • 3
    Digitale Medien
    Digitale Medien
    Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer (1994)
    Springer
    Investigational new drugs 12 (1994), S. 129-132 
    Details
    ISSN: 1573-0646
    Schlagwort(e): cis-platinum ; mitoxantrone ; breast cancer ; phase I-II trial
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Chemie und Pharmazie , Medizin
    Notizen: Summary The Southwest Oncology Group studied the response rate and toxicity of mitoxantrone (7.5 or 10 mg/m2 to 12.0 mg/m2) and cis-platinum (100 mg/m2) in 30 patients with advanced breast cancer as second-line therapy. There were 2 partial responses in 29 eligible patients. Toxicity was considerable, with 27 patients having grade 3 or 4 toxicity. Grade 3–4 toxicity included vomiting, thrombocytopenia, granulocytopenia, leukopenia and anemia. The combination of mitoxantrone plus cis-platinum has minimal activity as second-line therapy in metastatic breast cancer.
    Materialart: Digitale Medien
    URL: http://dx.doi.org/10.1007/BF00874442
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Artikel (Nationallizenzen)
    Volltext
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...